to various healthcare fields, ranging from
disease prediction and diagnosis to prognosis.
TLBM (Time-Labeled BioMarker)
TLBM (Time-Labeled BioMarker) allows for disease prevention solutions through predictive biomarkers and the rapid discovery of diagnostic biomarkers by comparing data before and after disease onset.
- By determining disease risk based on changes over time and lifestyle habits, to provide solutions for disease prevention and healthcare management can be provided.
- The discovered TLBM can be used to quickly identify disease diagnostic biomarkers that can be applied in actual clinical settings.
Predictive Biomarker
Diagnostic Biomarker
Framework
The TLBM framework utilizes time-series data to predict disease risk over time and offers a healthcare management solution that can manage risk by age group.
-
Genetic risk score
-
Time-integrated risk score
Device and method for generating disease onset information based on time-dependent associations using a polygenic risk score (Application No. 10-2021-0148683) and 9 others.*
TLBM Gastric Cancer Biomarker Case
(out-licensing completed)
The gastric cancer TLBM identified by Basgenbio has a risk ratio of more than 17 times for the group with high-risk compared to the normal group; its powerful advantage is the ability to screen the disease in relatively young age groups.
-
17 times
- Calculating disease risk
- For the group with risk traits, the risk is over 17 times higher.
-
From ≥40 y/o
- Identifying high-risk disease segments by age group
- Risk increases rapidly from the age of 40 for both normal and group with high-risk.
| BAS-GC-0001 | 40-49 y/o | 50-59 y/o | 60-69 y/o | |
|---|---|---|---|---|
|
RISK(CT) (N=226) |
Incidence rate | 25.31% | 40.50% | 66.36% |
| 95% CI | 0.19-0.31 | 0.34-0.47 | 0.48-0.78 | |
|
NORMAL(CC) (N=32,491) |
Incidence rate | 0.31% | 1.66% | 16.62% |
| 95% CI | 0.00-0.00 | 0.01-0.02 | 0.12-0.21 | |
TLBM Discovery and Commercialization Process
-
Disease Prediction and
Health Management Business - Early Disease Diagnosis Business
- Disease Diagnosis Business
- Disease Prognosis Prediction Business
TLBM Pipeline
| Category | Disease | Marker | Selecting Disease |
Discovering Biomarker |
Prediction Genetic Risk |
Calculating Age-Specific Risk Changes |
Cross Validating |
Licensing Out |
|---|---|---|---|---|---|---|---|---|
| Cancer | Gastric Cancer | BAS-GC-0001~10 |
Completion of L/O
|
|||||
| Breast Cancer | BAS-BC-0001~12 |
Patent Application Process
|
||||||
| Colorectal Cancer | BAS-CRC-0001~10 |
Patent Application Process
|
||||||
| Liver Cancer | BAS-LC-0001~10 |
Patent Application Process
|
||||||
| Thyroid Cancer | BAS-TC-0001~10 |
Patent Application Process
|
||||||
| Prostate Cancer | BAS-PC-0001~05 |
Patent Application Process
|
||||||
| Cardio- cerebrovasc ular Disease |
Ischemic Heart Disease |
BAS-IHD-0001~32 |
Patent Application Process
|
|||||
| Stroke | BAS-STR-0001~08 |
Patent Application Process
|
||||||
| Acute Myocardial Infarcation |
BAS-aMI-0001~12 |
Patent Application Process
|
||||||
| Autoimmune Disease |
Inflammatory Bowel Disease |
BAS-IBD-XXXX |
|
|||||
| Rheumatold Arthritis |
BAS-RA-XXXX |
|
||||||
| Metabolic Disease |
Gout | BAS-GT-XXXX |
|
Credit
- Project Manager
- Jungoh Kim, Ph.D.
- Project Assistant
- Jihye Lee
- Data Analyst
- Eunbyeol Lee, Yujeong Shim